Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Molbio Diagnostics Ltd (MOLBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544866 NSE: MOLBIO Medical Equipment/Supplies/Accessories | Small Cap | Molbio Diagnostics Share Price
₹1,032.40 -7.95 (-0.76%)
As on 20-Aug'26 16:59
Molbio Diagnostics Ltd (MOLBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544866 NSE: MOLBIO Medical Equipment/Supplies/Accessories | Small Cap | Molbio Diagnostics Share Price
₹1,032.40 -7.95 (-0.76%)
As on 20-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹11,897 Cr.
Current Price
₹1,032.4
52-Week Low / High
₹926 / 1,175
TTM EPS
₹12.6
TTM Sales
₹1,313 Cr.
Book Value per Share
₹115.8
P/E Ratio
82.26
In line with its 5-year historical median
Industry PE
121.3
Price to Book (P/B)
8.91
Lower than its 5-year historical median
Price to Sales (P/S)
9.06
In line with its 5-year historical median
EV/EBITDA
46.70
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
13.61%
Return on Capital Employed (ROCE)
17.82%
Return on Assets (ROA)
9.78%
Operating Profit Margin
19.7%
Net Profit Margin
11.01%
Gross Profit Margin
17.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
35.23%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
11.62%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
3.44%
Asset Quality
Promoter Holding
41.29%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,323 Cr.
Equity
₹11.5 Cr.
Face Value
₹1
All Time Low / High
₹925.80 / 1175.00
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Molbio Diagnostics Ltd a good quality company?
Molbio Diagnostics Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Molbio Diagnostics Ltd performance compare with that of its Peers?
Revenue growth of Molbio Diagnostics Ltd vs industry peers?
Molbio Diagnostics Ltd revenue CAGR is 59.03%, compared to the industry median CAGR of 13.29%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Molbio Diagnostics Ltd?
Promoters hold 41.29% of the Molbio Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Molbio Diagnostics Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Molbio Diagnostics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 3.6% | 18.7% | 20.5% | 17.8% | - |
| Value Creation Index ⓘ | -0.7 | 0.4 | 0.5 | 0.3 | - |
Growth Parameters ⓘ |
|||||
| Sales ⓘ | 327 | 756 | 971 | 1,313 | 1,313 |
| Sales YoY Gr. | - | 131.6% | 28.4% | 35.2% | - |
| Adj EPS ⓘ | 1.4 | 11.5 | 13.1 | 13.5 | 12.6 |
| YoY Gr. | - | 721.4% | 14.3% | 2.4% | - |
| BVPS (₹) ⓘ | 65.5 | 75.4 | 87.8 | 100.6 | 115.8 |
| Adj Net Profit ⓘ | 15.8 | 130 | 148 | 152 | 145 |
| Cash Flow from Ops. ⓘ | 67.9 | 37.7 | 249 | -38 | - |
| Debt/CF from Ops. ⓘ | 0.8 | 1.8 | 0.1 | -8.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 59% | 35.2% | ||||
| Adj EPS ⓘ | NA | NA | 112.6% | 2.4% | ||||
| BVPSⓘ | NA | NA | 15.4% | 14.7% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.1 | 16.3 | 16.1 | 14.3 | 11.6 |
| Op. Profit Mgn % ⓘ | 12.4 | 27 | 23.6 | 19.7 | NAN |
| Net Profit Mgn % ⓘ | 4.8 | 17.1 | 15.3 | 11.6 | 11 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0 | 0.3 | - |
| Working Cap Days ⓘ | 0 | 347 | 291 | 250 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 216 | 155 | 112 | 0 |
Valuation of Molbio Diagnostics - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|
| Sales | 327 | 756 | 971 | 1,313 |
| Operating Expenses ⓘ + | 286 | 553 | 746 | 1,062 |
| Operating Profit ⓘ | 40 | 204 | 226 | 252 |
| Operating Profit Margin (%) | 12.3% | 26.9% | 23.2% | 19.2% |
| Other Income ⓘ + | 8 | 7 | 6 | 8 |
| Interest ⓘ | 6 | 8 | 9 | 23 |
| Depreciation ⓘ | 19 | 24 | 26 | 36 |
| Profit Before Tax ⓘ | 23 | 152 | 188 | 198 |
| Tax ⓘ | 7 | 41 | 48 | 53 |
| Profit After Tax | 16 | 111 | 140 | 145 |
| PAT Margin (%) | 4.8% | 14.7% | 14.4% | 11.0% |
| Adjusted EPS (₹) | 1.4 | 9.9 | 12.4 | 12.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 739 | 850 | 990 | 1,135 | |||||||
| Debt + | 53 | 56 | 6 | 315 | |||||||
| Minority Interest | 0 | 0 | 0 | 0 | |||||||
| Trade Payables | 75 | 96 | 235 | 180 | |||||||
| Others Liabilities ⓘ | 48 | 52 | 35 | 63 | |||||||
| Total Liabilities ⓘ | 913 | 1,054 | 1,266 | 1,692 | |||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 189 | 176 | 215 | 257 | |||||||
| CWIP ⓘ | 0 | 2 | 18 | 6 | |||||||
| Investments ⓘ | 54 | 54 | 95 | 317 | |||||||
| Inventories | 328 | 293 | 410 | 397 | |||||||
| Trade Receivables | 173 | 360 | 228 | 359 | |||||||
| Cash Equivalents | 5 | 18 | 111 | 109 | |||||||
| Others Assets ⓘ | 165 | 152 | 190 | 248 | |||||||
| Total Assets ⓘ | 913 | 1,054 | 1,266 | 1,692 | |||||||
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 68 | 38 | 249 | -38 |
| Cash Flow From Investing Activity ⓘ + | -51 | -31 | -98 | -256 |
| Cash Flow From Financing Activity ⓘ + | 31 | -24 | -17 | 292 |
| Net Cash Flow ⓘ | 48 | -18 | 133 | -2 |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.1 | 13.99 | 15.2 | 13.61 | ||||||
| ROCE (%) | 3.63 | 18.66 | 20.47 | 17.82 | ||||||
| Asset Turnover Ratio | 0.36 | 0.77 | 0.86 | 0.9 | ||||||
| PAT to CFO Conversion(x) | 4.25 | 0.34 | 1.78 | -0.26 | ||||||
| Working Capital Days | ||||||||||
| Receivable Days | 193.70 | 128.80 | 107.20 | 80 | ||||||
| Inventory Days | 366.30 | 149.70 | 128.10 | 110.20 | ||||||
| Payable Days | 201.40 | 114.60 | 159.30 | 149.90 | ||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Molbio Diagnostics Ltd FAQs
The current trading price of Molbio Diagnostics on 20-Aug-2026 16:59 is ₹1,032.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Aug-2026 the market cap of Molbio Diagnostics stood at ₹11,897.4 Cr
The latest P/E ratio of Molbio Diagnostics as of 19-Aug-2026 is 82.26.
The latest P/B ratio of Molbio Diagnostics as of 19-Aug-2026 is 8.91.
The 52-week high of Molbio Diagnostics is ₹1,175 and the 52-week low is ₹925.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Molbio Diagnostics is ₹1,313 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Molbio Diagnostics Ltd is a average quality company.
The key valuation ratios of Molbio Diagnostics Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Molbio Diagnostics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Molbio Diagnostics Ltd
Molbio Diagnostics was originally incorporated as ‘Molbio Diagnostics Private Limited’ at Panaji, as a private limited company on October 20, 2000. Thereafter, the company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of the shareholders held on November 22, 2024, and the name of the company was changed to Molbio Diagnostics Limited on January 16, 2025.
The company is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. It has developed its ‘Truenat’ platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour. Truenat is patented in many countries for the diagnosis of multiple infectious and non-communicable diseases. It offers molecular testing for diseases, including tuberculosis (TB), COVID, Hepatitis B and C, Human immunodeficiency virus (HIV), and Human Papillomavirus (HPV) with multiple assays.
It also provides devices, enabling radiology, digital pathology and breast health screening, through its subsidiaries, Prognosys and OptraScan and collaboration partner - UE Lifesciences. The company derives its revenues from the sale of its ‘Truenat’ platform, which is designed to work exclusively with its range of ‘Truenat’ test kits that generate recurring revenues. A key feature of its platform is its versatility in diagnostic applications accommodating tests for various infectious and non-communicable diseases. Its platform is designed to connect wirelessly to help healthcare providers manage clinical data and workflow online. This could assist with the transmission of ‘notifiable infections’ to public health authorities to facilitate the tracking of reportable diseases.
Business area of the company
The company is mainly engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-ray equipment's, single / dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, etc.
Products of the company
- Truenat platform
- Truenat Test Kits
- Ultraportable X-ray systems
- Mobile X-ray systems
- Fixed X-ray systems
- Ceiling suspended X-ray systems
- High-frequency C-arm systems
- DR retrofit panels
Awards, accreditations and recognition
- 2019: Recognised as ‘Top 10 In-Vitro Diagnostic Technology Solution Providers - 2019’ by Medtech Outlook magazine.
- 2020: Awarded ‘Product of the Year Award’ for TrueNat by BioSpectrum.
- 2021: Awarded ‘Healthcare Award 2021’ in the category of outstanding research in healthcare: COVID 19- National at the Healthcare Awards conducted by the Economic Times.
- 2022: Awarded ‘Excellence in Innovation in Medical Technology - Company’ award at the 6th Healthcare Excellence Awards conducted by BW Healthcare World.
- 2023: Awarded ‘Good Samaratian Award’ at the 2nd Custodians of Humanity Awards conducted by Integrated Global Healthcare Mission.
- 2023: Received ‘Certificate of Recognition’ by Burgundy Private Hurun India 500.
- 2024: Awarded the ‘Change Maker Awards’ by the Hindu Group.
- 2025: Received ‘Certificate of Recognition’ by ASK Private Wealth and Hurun India in the ASK Private Wealth Hurun India Unicorn and Future Unicorn Report 2025.
- 2025: Awarded the ‘2024 Kochon Prize’ by the Stop TB Partnership for outstanding innovation and excellence towards ending TB.
- 2026: Awarded the ‘Deep-Tech Company of the year’ by VCCircle Edge 2.0 at VCCircle Awards 2026.
History and milestones
- 2000: Incorporation of the company.
- 2000: The company’s R&D arm, Bigtec Private Limited, one of its Subsidiaries commenced its operations.
- 2005: Bigtec directs its focus to chip-based PCR research.
- 2009: Bigtec develops a ‘lab-on-a-chip’ model.
- 2011: Entered into a joint venture agreement dated August 1, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited.
- 2013: Launch of the semi-automatic PCR device ‘Truelab Uno’.
- 2015: Amalgamation of Bigtec Innovations Private Limited with the company.
- 2017: Expert Committee on TB Diagnostics recommended the use of the ‘TrueNat MTB’ and ‘TrueNat MTB-Rif’ in the National Tuberculosis Elimination Programme (at the time known as the Revised National Tuberculosis Control Programme).
- 2018: Launch of fully- automatic PCR device ‘Truelab Uno’ and approved by the Indian Council for Medical Research (ICMR).
- 2019: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
- 2019: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time duplex PCR test for human papillomavirus high risk types 16, 31 and 18, 45 from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
- 2019: Investment by India Business Excellence Fund III in the company.
- 2020: World Health Organisation endorsed TrueNat as the primary diagnostic test for MTB and MTB-RIF.
- 2020: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for beta coronavirus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
- 2020: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for HIV-1 virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
- 2022: Investment by V Sciences Investments Pte. Ltd. in the company.
- 2023: Acquisition of Prognosys Medical Systems Private Limited to venture into radiology equipment.
- 2023: Acquisition of Prognosys Healthcare (India) Private Limited.
- 2024: Launched ‘Edge’, a scaleup partnership initiative between the company and Bigtec.
- 2024: Investment of 19.68% of the paid-up equity share capital of OptraScan, INC to diversify to digital pathology scanners.
- 2025: First Indian company to receive the Class C IVDR (EU 2017/746) Technical Documentation Assessment Certificate for Truenat CT/NG which has been issued by TUV SUD Product Service GmbH.
- 2025: Investment of an additional 40.32% of the paid-up equity share capital of OptraScan INC.
- 2025: Prognosys Medical Systems Private Limited received US FDA 510(k) clearance for PRORAD ATLAS ULTRAPORTABLE AND ULTRAPORTABLE PLUS.
- 2026: Prognosys Medical Systems Private Limited received EU Quality Management System certification under EU MDR 2017/745 for its PRORAD range of radiology systems.
- 2026: Truenat HR-HPV Plus meets International Agency for Research on Cancer (IARC) validation criteria in multicentre study.
- 2026: The company entered into a collaboration and license agreement with Equine Biotech Private Limited for development of veterinary diagnostic products, including assay design and validation.
- 2026: OptraScan, INC received US FDA 510(k) clearance (K260755) for its OptraSCAN System.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
